The new definition of dominant stricture in primary sclerosing cholangitis: Prevalence and clinical significance
Liver International · 2024
DOI: 10.1111/liv.15985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Mathias Thylin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Abdominal Center, Helsinki University and Helsinki University Hospital HUS, Helsinki, Finland. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cholangiopancreatography, Endoscopic Retrograde. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns minne, Finska Läkaresällskapet.
Abstract (Originalsprache)
Background and Aims A new definition of dominant stricture (NDS) has recently been defined for patients with primary sclerosing cholangitis (PSC). Prevalence and clinical features of this, compared to traditional dominant stricture (TDS), have not been reported.
Methods
In this single‐centre longitudinal prospective cohort study, all PSC patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) between October 2021 and 2022 were recruited. Symptoms of cholestasis, laboratory values (P‐alkaline phosphatase, P‐Bilirubin), Helsinki PSC‐score, brush cytology findings and need for endoscopic therapy (i.e. dilation, stenting) were prospectively collected.
Results
Overall, 228 patients with PSC underwent 248 ERCPs. NDS was detected in 43 (17%; 36 patients) and TDS without NDS (TDS group) was detected in 62 (25%; 58 patients) ERCPs, respectively; in the remaining 143 ERCPs, neither TDS nor NDS was seen (no dominant stricture [NoDS] group). PSC duration (median 8 years) and patient's age did not differ between the three groups; males presented more often with NDS. Patients with NDS were more often symptomatic, had higher cholestatic liver enzymes, advanced bile duct disease and markers of biliary inflammation ( p < .001). Patients with NDS needed dilation (81%) and stenting (21%) more often than the TDS group (60% and 5%, respectively). Dysplasia in brush cytology was more common in TDS (5%) and NDS (9%) than in NoDS (3%) groups ( p = .04), but did not differ between TDS and NDS groups.
Conclusions
Dominant stricture according to the new definition developed in 17% of PSC patients in our cohort and identifies patients with more advanced disease, biliary inflammation and need of endo‐therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Abdominal Center, Helsinki University and Helsinki University Hospital HUS, Helsinki, Finland.
- Department of Public Health, Kuopio University Hospital, Kuopio, Finland.
- Department of Pathology, Helsinki University and Helsinki University Hospital HUS, Helsinki, Finland.
ORCID-Profile: Mathias Thylin, Martti Färkkilä, Nina Barner-Rasmussen, Andrea Tenca
Förderung
- Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns minne
- Finska Läkaresällskapet
Zitieren
APA
Thylin, M., Färkkilä, M., Kautiainen, H., Barner-Rasmussen, N., Jokelainen, K., Puustinen, L., Boyd, S., Arola, J., & Tenca, A. (2024). The new definition of dominant stricture in primary sclerosing cholangitis: Prevalence and clinical significance. Liver International. https://doi.org/10.1111/liv.15985
Vancouver
Thylin M, Färkkilä M, Kautiainen H, Barner-Rasmussen N, Jokelainen K, Puustinen L, et al. The new definition of dominant stricture in primary sclerosing cholangitis: Prevalence and clinical significance. Liver International. 2024. doi:10.1111/liv.15985
BibTeX
@article{Thylin2024,
author = {Thylin, Mathias and Färkkilä, Martti and Kautiainen, Hannu and Barner-Rasmussen, Nina and Jokelainen, Kalle and Puustinen, Lauri and Boyd, Sonja and Arola, Johanna and Tenca, Andrea},
title = {The new definition of dominant stricture in primary sclerosing cholangitis: Prevalence and clinical significance},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15985}
}
EUVIMED